ProMIS Neurosciences is engaged in applying its technology platform to build a portfolio of antibody therapies, vaccines, and other antibody-based therapies in neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, Parkinson's disease, Lewy body dementia, frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The PMN stock yearly return is shown above.
The yearly return on the PMN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PMN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|